Advanced search
Publication Cover
Acta Oto-Laryngologica Volume 121, 2001 - Issue 8
Submit an article Journal homepage
3
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Appearance of Bax Protein After Preoperative Chemoradiotherapy is a Prognostic Factor in Maxillary Cancer

Toshihisa Ito, Shigeharu Fujieda, Hideaki Tsuzuki, Hiroshi Sunaga, Masaru Fukuda, Hitoshi Saito Department of First Pathology, Fukui Medical University, Fukui, Japan
Pages 967-972 | Published online: 08 Jul 2009

  • Raff MC. Social controls on cell survival and cell death. Nature 1992; 356: 397-400.
  • Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
  • Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-9.
  • Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89: 7491-5.
  • Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GW. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-8.
  • Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345-7.
  • Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature 1992; 358: 83-6.
  • Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell 1995; 80: 293-9.
  • Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805.
  • Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homology, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
  • Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.
  • Ito T, Fujieda S, Tsuzuki H, et al. Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma. Cancer Lett 1999; 140: 81-91.
  • Staibano S, Mignogna MD, Muzio L1, et al. Overexpression of cyclin-D1, bcl-2, and bax proteins, proliferating cell nuclear antigen (PCNA), and DNA-ploidy in squamous cell carcinoma of the oral cavity. Hum Pathol 1998; 29: 1189-94.
  • Xie X, Clausen OPF, Angelis PD, et al. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999; 86: 913-21.
  • Fujieda S, Sunaga H, Tsuzuki H, Tanaka N, Saito H. Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma. Clin Cancer Res 1998; 4: 1583-90.
  • Fujieda S, Lee K, Sunaga H, et al. Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer 1999; 85: 1439-45.
  • Fujieda S, Inuzuka M, Tanaka N, et al. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer 1999; 84: 315-20.
  • Fujieda S, Sunaga H, Tsuzuki H, et al. Expression of Fas (CD95) ligand is correlated with IL-10 and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma. Cancer Lett 2000; 161: 73-81.
  • Bartek J, Bartkova B, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699-703.
  • Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene Bax is associated with poor response rate to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-8.
  • Jäcket MC, Dorudian MA, Marx D, Brinck U, Schauer A, Steineer W. Spontaneous apoptosis in laryngeal squamous cell carcinoma is independent of bcl-2 and bax protein expression. Cancer 1999; 85: 591-9.
  • Yin C, Knudoson CM, Korsmeyer SJ, Dyke TV. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-40.
  • Bargou RC, Wagener C, Bommert K, et al. Overexpression of the death-promoting gene bax-a which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 1996; 11: 2651-9.
  • Sugimoto C, Fujieda S, Seki M, et al. Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo. Int J Cancer 1999; 82: 860-7.
  • Homma A, Furuta Y, Oridate N, et al. Prognostic significance of clinical parameters and biologic markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 1999; 5: 801-6.
  • Costa A, Licitra L, Veneroni S, et al. Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancer. Int J Cancer 1998; 79: 619-23.
  • Sakakura C, Sweeney EA, Shirahama T, et al. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 1996; 67: 101-5.
  • Gasparini G, Weidner N, Maluta S, et al. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 1993; 55: 739-44.
  • Spafford MF, Koeppe J, Pan Z, Archer PG, Meyers AD, Franklin WA. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1996; 122: 627-32.
  • Field JK, Pavelic ZP, Spandidos DA, Stambrook PJ, Jones AS, Gluckman JL. The role of the p53 tumor suppressor gene in squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 1993; 119: 1118-22.
  • Lassaletta L, Brandariz JA, Benito A, et al. p53 expression in locally advanced pharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1999; 125: 1356-9.
  • Gallo O, Chiarelli I, Boddi V, et al. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer 1999; 84: 573-9.
  • Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser46-phosphorylated p53. Cell 2000; 102: 849-62.
  • Gasparini G, Bevilacqua P, Bonoldi E, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1995; 1: 1375-83.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.